Union Savings Bank lifted its position in Danaher Corporation (NYSE:DHR – Free Report) by 258.6% in the 3rd quarter, Holdings Channel.com reports. The fund owned 7,883 shares of the conglomerate’s stock after acquiring an additional 5,685 shares during the period. Danaher makes up 0.7% of Union Savings Bank’s investment portfolio, making the stock its 24th largest position. Union Savings Bank’s holdings in Danaher were worth $1,746,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also made changes to their positions in DHR. BlackRock Inc. acquired a new stake in shares of Danaher during the 2nd quarter valued at approximately $10,492,520,000. Jupiter Topco LLC acquired a new position in Danaher in the second quarter worth $1,456,317,000. Generation Investment Management LLP acquired a new position in Danaher in the second quarter worth $1,287,949,000. Bank of America Corp DE bought a new stake in Danaher during the second quarter valued at $993,846,000. Finally, Legal & General Group Plc bought a new stake in Danaher during the second quarter valued at $801,056,000. 79.05% of the stock is currently owned by institutional investors.
More Danaher News
Here are the key news stories impacting Danaher this week:
- Positive Sentiment: Potential earnings beat: Zacks says Danaher has a strong earnings-surprise history and currently shows the two indicators—earnings estimate revisions and an Earnings ESP reading—that can signal another quarterly beat. Analysts expect earnings growth in the upcoming report. Will Danaher Beat Estimates Again in Its Next Earnings Report?
- Positive Sentiment: NVIDIA collaboration supports AI strategy: Danaher announced a partnership with NVIDIA to combine its scientific instruments, laboratory automation, workflow software and domain expertise with NVIDIA’s accelerated computing and AI technologies. The goal is to advance autonomous science and speed up scientific discovery, creating a potentially important long-term growth opportunity in life-science research. Danaher Collaborates with NVIDIA to Advance Autonomous Science
- Positive Sentiment: Autonomous laboratory plans: Danaher plans to launch its first AI-powered autonomous laboratory, with commercial-scale operations expected in early 2027. The initiative could improve laboratory productivity and strengthen Danaher’s positioning in AI-enabled drug discovery, though meaningful revenue benefits are likely longer term. How to Invest in AI Drug Discovery
- Neutral Sentiment: Analyst support: Morgan Stanley maintained its $240 price target for DHR, indicating continued confidence in the company’s outlook but no new change in the valuation view. Morgan Stanley Keeps $240 Target for Danaher Stock
- Neutral Sentiment: Board expansion: Danaher expanded its board to 13 members and appointed new directors, a governance development with limited immediate earnings impact. Danaher Enhances Board With New Director Appointments
Analyst Ratings Changes
Get Our Latest Stock Report on Danaher
Danaher Stock Performance
DHR traded up $1.81 during trading on Wednesday, reaching $224.65. 3,595,884 shares of the company were exchanged, compared to its average volume of 4,457,645. The stock has a market cap of $157.93 billion, a P/E ratio of 39.90, a PEG ratio of 2.78 and a beta of 0.76. The firm has a 50 day moving average of $212.92 and a 200 day moving average of $195.39. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. Danaher Corporation has a 52 week low of $160.93 and a 52 week high of $242.80.
Danaher (NYSE:DHR – Get Free Report) last posted its earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. The company had revenue of $6.26 billion for the quarter, compared to analysts’ expectations of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%. The firm’s quarterly revenue was up 5.5% compared to the same quarter last year. During the same period last year, the business posted $0.77 earnings per share. On average, sell-side analysts forecast that Danaher Corporation will post 8.53 EPS for the current fiscal year.
Danaher Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend is Wednesday, September 30th. Danaher’s payout ratio is presently 28.42%.
Danaher Profile
Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.
The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.
Featured Articles
- Five stocks we like better than Danaher
- Tesla Wants to Make Its Own Chips—What Could Go Wrong?
- IREN Limited’s AI Pivot Gains Traction—But Can Its Data Centers Deliver?
- PBF Energy’s Stunning Rally Faces a Critical Test
- Citi Stock Falls Despite Earnings Beat: What Investors Need to Know
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.
